TIMI IIB

OBJECTIVES:

To compare the effects of an invasive vs. conservative strategy following thrombolysis with rtPA among patients with ST elevation myocardial infarction.

To compare the effect of immediate vs. delayed (6 days) metoprolol therapy among patients with ST elevation myocardial infarction treated with rtPA (a substudy of the TIMI II trial).

View/Download
_______________________________________________________________________________

1. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989;320:618-27.
   | Abstract | Request Reprints |
   

2. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Roberts R, Rogers WJ, Mueller HS, et al. Circulation 1991;83:422-37.
   | Abstract | Request Reprints |

   
   
3. Demonstration of reperfusion after thrombolysis with technetium-99m isonitrile myocardial imaging. Kayden DS, Mattera JA, Zaret BL, Wackers FJ. J Nucl Med 1988;29:1865-7.
   | Abstract | Request Reprints |
   
   
4. Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Gibbons RJ, Verani MS, Behrenbeck T, et al. Circulation 1989;80:1277-86.
   | Abstract | Request Reprints |
   
   
5. Feasibility and safety of emergency interhospital transport of patients during early hours of acute myocardial infarction. Gore JM, Corrao JM, Goldberg RJ, et al. Arch Intern Med 1989;149:353-5.
   | Abstract | Request Reprints |
   
   
6. An analysis of time delays preceding thrombolysis for acute myocardial infarction. Sharkey SW, Bruneete DD, Ruiz E, et al. JAMA 1989;262:3171-4.
   | Abstract | Request Reprints |
   
   
7. Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: efficacy for noninvasive assessment of thrombolytic therapy. Wackers FJ, Gibbons RJ, Verani MS, et al. J Am Coll Cardiol 1989;14:861-73.
   | Abstract | Request Reprints |
   
   
8. Thrombolysis in Myocardial Infarction (TIMI) phase II trial: outcome comparison of a "conservative strategy" in community versus tertiary hospitals. The TIMI Research Group. Feit F, Mueller HS, Braunwald E, et al. J Am Coll Cardiol 1990;16:1529-34.
   | Abstract | Request Reprints |

   
   

9. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. Hillis LD, Forman S, Braunwald E. J Am Coll Cardiol 1990;16:313-5.
   | Abstract | Request Reprints |
   

10. Dual isotope thallium and indium antimyosin SPECT imaging to identify acute infarct patients at further ischemic risk. Johnson LL, Seldin DW, Keller AM, et al. Circulation 1990;81:37-45.
    | Abstract | Request Reprints |
    
    

11. Silent left ventricular dysfunction during routine activity after thrombolytic therapy for acute myocardial infarction. Kayden DS, Wackers FJ, Zaret BL. J Am Coll Cardiol 1990;15:1500-7.
    | Abstract | Request Reprints |
    
    

12. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Lawler CM, Bovill EG, Stump DC, Collen DJ, Mann KG, Tracy RP. Blood 1990;76:1341-8.
    | Abstract | Request Reprints |
    
    

13. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Bovill EG, Terrin ML, Stump DC, et al. Ann Intern Med 1991;115:256-65.
    | Abstract | Request Reprints |

    
    
14. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Gore JM, Sloan M, Price TR, et al. Circulation 1991;83:448-59.
    | Abstract | Request Reprints |
    
    
15. Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators. Rogers WJ, Babb JD, Baim DS, et al. J Am Coll Cardiol 1991;17:1007-16.
    | Abstract | Request Reprints |
    
    
16. Left ventricular function and early cardiac events as a function of time to treatment with t-PA: A report from TIMI II. Timm TC, Ross R, McKendall GR, Braunwald E, Williams DO, and the TIMI Investigators. Circulation 1991;84:II-230.
    | Request Reprints |
    
    
17. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. Zaret BL, Wackers FJ, Terrin ML, et al. J Am Coll Cardiol 1995;26:73-9.
    | Abstract | Request Reprints |
    
    
18. Coronary angioplasty performed within the thrombolysis in Myocardial Infarction II study. Baim DS, Diver DJ, Feit F, et al. Circulation 1992;85:93-105.
    | Abstract | Request Reprints |
    
    
19. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II. Berger PB, Ruocco NA, Jr., Ryan TJ, Frederick MM, Jacobs AK, Faxon DP. J Am Coll Cardiol 1992;20:533-40.
    | Abstract | Request Reprints |

    
    

20. Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study. Kleiman NS, Terrin M, Mueller H, et al. J Am Coll Cardiol 1992;19:1129-35.
    | Abstract | Request Reprints |
    

21. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Mueller HS, Cohen LS, Braunwald E, et al. Circulation 1992;85:1254-64.
    | Abstract | Request Reprints |
    
    

22. Invasive versus conservative strategy after thrombolytic therapy for acute myocardial infarction in patients with antecedent angina. A report from Thrombolysis in Myocardial Infarction Phase II (TIMI II). Ruocco NA, Jr., Bergelson BA, Jacobs AK, Frederick MM, Faxon DP, Ryan TJ. J Am Coll Cardiol 1992;20:1445-51.
    | Abstract | Request Reprints |
    

23. Modifiers of timing and possible triggers of acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Study Group. Tofler GH, Muller JE, Stone PH, et al. J Am Coll Cardiol 1992;20:1049-55.
    | Abstract | Request Reprints |
    
    

24. One-year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase II Trial. Williams DO, Braunwald E, Knatterud G, et al. Circulation 1992;85:533-42.
    | Abstract | Request Reprints |
    

25. Assessment of global and regional left ventricular performance at rest and during exercise after thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II Study. Zaret BL, Wackers FJ, Terrin ML, et al. Am J Cardiol 1992;69:1-9.
    | Abstract | Request Reprints |
    

26. Frequency and significance of during inferior wall left ventricular myocardial infarction treated with thrombolytic therapy (results from the thrombolysis in myocardial infarction [TIMI] II trial). The TIMI Research Group. Berger PB, Ruocco NA, Jr., Ryan TJ, et al. Am J Cardiol 1993;71:1148-52.
    | Abstract | Request Reprints |

    
    
27. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Podrid PJ. J Am Coll Cardiol 1993;22:1773-9.
    | Abstract | Request Reprints |
    
    
28. Impact of treatment strategy on predischarge exercise test in the Thrombolysis in Myocardial Infarction (TIMI) II Trial. Chaitman BR, McMahon RP, Terrin M, et al. Am J Cardiol 1993;71:131-8.
    | Abstract | Request Reprints |
    
    
29. Race and prognosis after myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. Taylor HA, Chaitman BR, Rogers WJ, et al. Circulation 1993;88:1484-94.
    | Abstract | Request Reprints |
    
    
30. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. Terrin ML, Williams DO, Kleiman NS, et al. J Am Coll Cardiol 1993;22:1763-72.
    | Abstract | Request Reprints |
    
    
31. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Simoons ML, Maggioni AP, Knatterud G, et al. Lancet 1993;342:1523-8.
    | Abstract | Request Reprints |
    
    
32. Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators. Aguirre FV, McMahon RP, Mueller H, et al. Circulation 1994;90:78-86.
    | Abstract | Request Reprints |
    
    
33. Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. Becker RC, Terrin M, Ross R, et al. Ann Intern Med 1994;120:638-45.
    | Abstract | Request Reprints |
    
    
34. Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. Cox DA, Rogers WJ, Aguirre FV, Forman S, Solomon R, Zaret BL. Am J Cardiol 1994;73:729-36.
    | Abstract | Request Reprints |
    
    
35. Comparison of patients with < 60% to > or = 60% diameter narrowing of the myocardial infarct-related artery after thrombolysis. The TIMI Investigators. Schweiger MJ, McMahon RP, Terrin ML, et al. Am J Cardiol 1994;74:105-10.
    | Abstract | Request Reprints |
    
    
36. Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from The TIMI II Study. Aguirre FV, Younis LT, Chaitman BR, et al. Circulation 1995;91:2541-8.
    | Abstract | Request Reprints |
    
    
37. Coronary artery bypass graft surgery after thrombolytic therapy in the Thrombolysis in Myocardial Infarction Trial, Phase II (TIMI II). Gersh BJ, Chesebro JH, Braunwald E, et al. J Am Coll Cardiol 1995;25:395-402.
    | Abstract | Request Reprints |
    
    
38. Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. Hall C, Cannon CP, Forman S, Braunwald E. J Am Coll Cardiol 1995;26:1452-6.
    | Abstract | Request Reprints |
    
    
39. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators. Mueller HS, Forman SA, Menegus MA, Cohen LS, Knatterud GL, Braunwald E. J Am Coll Cardiol 1995;26:900-7.
    | Abstract | Request Reprints |
    
    
40. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Sloan MA, Price TR, Petito CK, et al. Neurology 1995;45:649-58.
    | Abstract | Request Reprints |
    
    
41. Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis in Myocardial Infarction (TIMI) phase II study. The TIMI Study Group. Zaret BL, Wackers FJ, Terrin ML, et al. J Am Coll Cardiol 1995;26:73-9.
    | Abstract | Request Reprints |
    
    
42. The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thromholysis in Myocardial Infarction Phase II (TIMI II) Trial.Callas PW, Tracy RP, Bovill EG, Cannon C, Thompson B, Mann KG. J Thromb Thrombolysis 1998;5:53-60.
    | Abstract | Request Reprints |
    
    
    
43. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. Tracy RP, Kleiman NS, Thompson B, et al. Am Heart J 1998;135:29-37.
    | Abstract | Request Reprints |